The Expression of Immune Checkpoint Receptors and Ligands in the Colorectal Cancer Tumor Microenvironment
暂无分享,去创建一个
S. Nakajima | Katsuharu Saito | K. Kono | M. Saito | H. Okayama | T. Momma | H. Onozawa | S. Fujita | W. Sakamoto | Misato Ito | Kosaku Mimura | Z. Saze | Aung Kyi Thar Min | Prajwal Neupane
[1] N. Syn,et al. Combined inhibition of PD-1/PD-L1, Lag-3, and Tim-3 axes augments antitumor immunity in gastric cancer–T cell coculture models , 2021, Gastric Cancer.
[2] S. Nakajima,et al. Therapeutic potential of anti-VEGF receptor 2 therapy targeting for M2-tumor-associated macrophages in colorectal cancer , 2020, Cancer Immunology, Immunotherapy.
[3] Yoshiyuki Suzuki,et al. Immune suppression caused by PD-L2 expression on tumor cells in gastric cancer , 2020, Gastric Cancer.
[4] D. Jäger,et al. Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability–High/Mismatch Repair–Deficient Metastatic Colorectal Cancer: KEYNOTE-164 , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] C. Murga-Zamalloa,et al. Expression of the checkpoint receptors LAG-3, TIM-3 and VISTA in peripheral T cell lymphomas , 2019, Journal of Clinical Pathology.
[6] Katsuharu Saito,et al. A subset of patients with MSS/MSI-low-colorectal cancer showed increased CD8(+) TILs together with up-regulated IFN-γ , 2019, Oncology letters.
[7] R. Takimoto,et al. Prognostic Factors for Colorectal Cancer Patients Treated With Combination of Immune-cell Therapy and First-line Chemotherapy: A Retrospective Study , 2019, AntiCancer Research.
[8] Z. Stadler,et al. Immunotherapy in colorectal cancer: rationale, challenges and potential , 2019, Nature Reviews Gastroenterology & Hepatology.
[9] D M Parkin,et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods , 2018, International journal of cancer.
[10] J. Roliński,et al. Immune-checkpoint inhibitors for combating T-cell dysfunction in cancer , 2018, OncoTargets and therapy.
[11] M. Sawyer,et al. Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] Xiao-li Zhang,et al. The coexpression of multi-immune inhibitory receptors on T lymphocytes in primary non-small-cell lung cancer , 2017, Drug design, development and therapy.
[13] J. Desai,et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. , 2017, The Lancet. Oncology.
[14] Xiandong Lin,et al. Prognostic significance of PD-L1 expression and tumor infiltrating lymphocyte in surgically resectable non-small cell lung cancer , 2017, Oncotarget.
[15] Daniel M. Corey,et al. PD-1 expression by tumor-associated macrophages inhibits phagocytosis and tumor immunity , 2017, Nature.
[16] Amy E Herr,et al. Profiling protein expression in circulating tumour cells using microfluidic western blotting , 2017, Nature Communications.
[17] M. Kloor,et al. The Immune Biology of Microsatellite-Unstable Cancer. , 2016, Trends in cancer.
[18] B. Vogelstein,et al. PD-1 blockade in tumors with mismatch repair deficiency. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] J. Hackney,et al. The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function. , 2014, Cancer cell.
[20] J. Colgan,et al. Regulation of T cell responses by the receptor molecule Tim-3 , 2014, Immunologic research.
[21] Jeffrey J Meyer,et al. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012. (5) , 2013 .
[22] Benjamin E. Gross,et al. Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.
[23] Steven J. M. Jones,et al. Comprehensive molecular characterization of human colon and rectal cancer , 2012, Nature.
[24] C. Drake,et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. , 2012, The New England journal of medicine.
[25] David C. Smith,et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.
[26] Benjamin E. Gross,et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.
[27] H. Pircher,et al. Extended Co-Expression of Inhibitory Receptors by Human CD8 T-Cells Depending on Differentiation, Antigen-Specificity and Anatomical Localization , 2012, PloS one.
[28] J. Kirkwood,et al. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+ T cell dysfunction in melanoma patients , 2010, The Journal of experimental medicine.
[29] Jenna M. Sullivan,et al. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity , 2010, The Journal of experimental medicine.
[30] V. Kuchroo,et al. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity , 2005, Nature Immunology.
[31] G. Freeman,et al. Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance , 2003, Nature Immunology.
[32] V. Kuchroo,et al. Tim-3 inhibits T helper type 1–mediated auto- and alloimmune responses and promotes immunological tolerance , 2003, Nature Immunology.
[33] A. Rotte,et al. Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[34] Y. Kawakami,et al. Melanoma Cells Control Antimelanoma CTL Responses via Interaction between TIGIT and CD155 in the Effector Phase. , 2016, The Journal of investigative dermatology.
[35] H. Clark,et al. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells , 2009, Nature Immunology.
[36] J. Hardcastle,et al. Colorectal cancer , 1993, Europe Against Cancer European Commission Series for General Practitioners.